FGI-106 tetrahydrochloride is a potent and broad-spectrum inhibitor with inhibitory activity against multiple viruses. FGI-106 tetrahydrochloride is active against Ebola , Rift Valley and Dengue Fever viruses with EC 50 s of 100 nM, 800 nM and 400-900 nM, respectively. FGI-106 tetrahydrochloride also inhibits non-hemorrhagic fever viruses HCV and HIV-1 with EC 50 s of 200 nM and 150 nM, respectively In Vitro Treatment with 2 μM FGI-106 mediated a 4 log reduction in infectious viral titers relative to matched controls, with an EC 90 for inhibition of viral killing of host cells (Vero E6 cells) estimated to be 0.6 μM. In cell-based assays, treatment with FGI-106 inhibits viral replication by divergent virus families, including positive and negative-strand RNA viruses. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo FGI-106 (0.1-5 mg/kg; intraperitoneal injection; treatments on days 2 and 5; C57BL/6 or BALB/c mice) treatment decreases mortality from Zaire EBOV in a dose-dependent manner . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male or female C57BL/6 or BALB/c mice (6-10 weeks of age) injected with EBOV (Ebola virus) Dosage: 0.1 mg/kg, 0.5 mg/kg, 1 mg/kg, 2 mg/kg, 5 mg/kg Administration: Intraperitoneal injection; treatments on days 2 and 5 Result: Decreased mortality from Zaire EBOV in a dose-dependent manner. Form:Solid IC50& Target:EC50: 100 nM (Ebola virus), 800 nM (Rift Valley virus), 400-900 nM (Dengue Fever virus), 200 nM (HCV) and 150 nM (HIV-1)